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Ectopic lipid deposition in muscle and liver is associated with the pathogenesis of type II diabetes. Hagberg
et al. (2012) report that targeting the vascular endothelial growth factor (VEGF)-B restores insulin sensitivity
and glucose tolerance by inhibiting endothelial-to-tissue lipid transport, opening promising avenues for
diabetes therapy.Type II diabetes represents a formidable
unmet medical health problem with more
than 300 million people estimated to
be affected worldwide. Individuals with
diabetes have an elevated risk of vascular
disease (atherosclerosis, stroke) and
other complications. Diabetes-related
deaths are expected to rise at an alarming
speed over the coming years. Insulin
resistance has been linked to accumula-
tion of toxic lipid intermediates (ceram-
ides, diacylglycerol) in skeletal muscle
and liver. Hence, strategies prevent-
ing lipid deposition may offer therapeutic
benefit but are not widely available
(Samuel and Shulman, 2012). Hagberg
et al. (2012) demonstrate that targeting
the vascular endothelial growth factor B
(VEGF-B) restores insulin sensitivity and
prevents type II diabetes by reducing lipid
accumulation in muscle.
How can an angiogenic growth factor
like VEGF-B be linked to diabetes?
VEGF-B was one of the later members of
the VEGF family to be identified, and
its activity remains poorly understood
(Fischer et al., 2008). It is expressed in
the heart, skeletal muscle, and brown fat
and binds to VEGF receptor-1 (VEGFR1;
flt-1) and its coreceptor neuropilin-1
(NRP1). Genetic studies indicate that
VEGF-B’s angiogenic capacity is contex-
tual and largely restricted to the heart,
while pharmacological blockade inhibits
ocular angiogenesis. In cancer, VEGF-B
is, however, anti-angiogenic. Overall, its
activity is less potent than other traditional
angiogenic signals, but it induces strong
arterialization of the coronary vascula-
ture in rats (Bry et al., 2010). Importantly,
VEGF-B overexpression in mouse but
not in rat hearts leads to hypertrophy and
signs of mitochondrial lipotoxicity, sug-gesting a possible role in cardiac metabo-
lism (Bry et al., 2010; Karpanen et al.,
2008). However, VEGF-B does not affect
mitochondrial function per se (Hagberg
et al., 2010; Karpanen et al., 2008). Rather,
it promotes lipid transport across the
endothelial barrier by upregulating the
fatty acid transport proteins (FATP)-
3/4 (Hagberg et al., 2010). Indeed, lipid
uptake and deposition in muscle were
reduced, and lipids were shunted to
white adipose tissue in VEGF-B-deficient
mice. Consequently, the fat mass and
body weight increased, and glucose
uptake to the heart was enhanced. These
initial observations prompted Hagberg
et al. (2012) to investigate the poten-
tial of anti-VEGF-B therapy for insulin
resistance.
In their follow-up study, Hagberg et al.
(2012) demonstrate that genetic defi-
ciency of VEGF-B in mouse models of
insulin resistance and type II diabetes,
including db/db diabetic mice (which
carry mutations in the leptin receptor
gene) andmice fedahigh-fat diet, reduces
lipid storage in muscle, heart, and
pancreas—but not liver. VEGF-B inhibi-
tion reduced plasma triglyceride and non-
esterified fatty acid levels and normalized
the HDL-c to LDL-c ratio, indicat-
ing a reduced risk for cardioavascular
pathology. However, the body weight of
VEGF-B-deficient mice on a high-fat diet
was increased. Nevertheless, VEGF-B
deficiency lowered blood glucose levels
without increasing insulin secretion and
restored insulin sensitivity and glucose
uptake in the muscle and heart.
Pharmacological inhibition of VEGF-B
via the administration of an anti-VEGF-B
antibody to db/db mice or rats fed a
high-fat diet largely phenocopied theCell Metabolism 16,genetic findings and enhanced insulin
sensitivity. In a preventive setting (predia-
betic db/dbmice), VEGF-B blockade pre-
vented the development of hypergly-
cemia, reduced lipid uptake in muscle,
improved glucose tolerance, and pro-
tected against dyslipidemia. In a thera-
peutic setting (diabetic db/db mice),
VEGF-B inhibition halted the progres-
sion of hyperglycemia and muscle lipid
uptake. In addition, VEGF-B blockade
improved pancreatic islet morphology,
restored insulin and glucagon expression
in the islets, and reduced islet cell death
in both models. In another high-fat diet
rat model, coincident initiation of the
high-fat diet and anti-VEGF-B treat-
ment normalized glucose tolerance
and glucose-stimulated insulin secretion,
reduced glucose infusion and disposal
rates in a hyperinsulinemic/euglycemic
clamp study, and promoted glucose
uptake in muscle—evidence of improved
insulin sensitivity. These results support
the idea that VEGF-B regulates lipid
uptake by muscles. Given that VEGF-B
regulates lipid transport across the endo-
thelium, the findings suggest that the
endothelium acts as a prominent barrier
controlling muscle lipid uptake. Further-
more, blocking VEGF-B provides a mech-
anism to ameliorate or even prevent type
II diabetes (Figure 1).
As with any breakthrough, this study
raises a number of questions. For in-
stance, is the effect of VEGF-B on trans-
endothelial lipid transport the onlymecha-
nism? VEGF-B has a poor angiogenic
activity in healthy conditions, but an effect
of this growth factor on the vasculature
in conditions of insulin resistance remains
possible. Another question is whether
VEGF-B can control insulin signaling inNovember 7, 2012 ª2012 Elsevier Inc. 553
Figure 1. VEGF Promotes Diabetes by Facilitating Lipid Uptake by Muscle
In diabetic rodents (left panel), vascular endothelial growth factor (VEGF)-B, expressed inmuscle, binds to VEGF receptor-1 (VEGFR1; flt-1) on endothelial cells to
increase the expression of fatty acid transport proteins (FATP). FATP increase lipid transport across the endothelium to the muscle, where it accumulates as lipid
droplets, resulting in insulin resistance and leading to increased blood glucose and pancreatic b cell death. VEGF-B blockade (right panel), using a neutralizing
antibody, prevents VEGF-B-mediated upregulation of FATP in the endothelium, thus reducing lipid transport to the muscle. As a result, lipid uptake in the muscle
is decreased, with a compensatory increase in glucose uptake, resulting in restored insulin sensitivity and leading to normalized blood glucose and preservation
of pancreatic islet area and function. Of note, peripheral adipose lipid uptake is consequently increased, leading to increased body weight. Similar data were
obtained after genetic deletion of VEGF-B.
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Previewsendothelial cells, a process known to in-
crease insulin delivery to muscle (Kubota
et al., 2011). Since insulin also promotes
lipid uptake in muscle, VEGF-B’s activity
might also depend on effects on in-
sulin. It would also be interesting to test
whether endothelial deletion of NRP1 or
VEGFR1, known to reduce the levels of
the FATP4 transport protein in vitro
(Hagberg et al., 2010), phenocopies the
protective effects of VEGF-B blockade
in vivo. Given that different VEGF-B-
deficient mouse strains exhibit distinct
phenotypes in baseline conditions (Aase
et al., 2001; Bellomo et al., 2000), a con-
firmation of the antidiabetic phe-
notype in another VEGF-B-deficient strain
would strengthen the current findings. It
would also be interesting to explore if
VEGF-B has additional prodiabetic
effects through other changes in endothe-
lial cells, perhaps modifying endothelial554 Cell Metabolism 16, November 7, 2012 ªcell metabolism or endothelial-to-adipo-
cyte differentiation, or altering vascular
inflammation, a process known to modify
insulin sensitivity.
For anti-VEGF-B treatment to be clini-
cally relevant, the data of the Hagberg
et al. (2012) paper should be relevant
for humans. While the authors paid
great effort to test various rodent models,
genetic association studies have not
yet overwhelmingly identified VEGF-B as
a possible risk factor for diabetes in
humans. Another clinically relevant ques-
tion is whether therapeutic blockade
of VEGF-B therapy is safe. Deficiency of
VEGF-B is well tolerated. Nonetheless,
VEGF-B has been implicated in neuro-
genesis and neuroprotection (Poesen
et al., 2008) and ischemic cardiac re-
vascularization, raising the question
whether VEGF-B blockade might worsen
diabetic neuropathy or ischemic heart2012 Elsevier Inc.disease. The role of VEGF-B in in-
hibiting tumor angiogenesis will also
deserve consideration. Overall, this work
places the endothelium and its regula-
tion by the VEGF-B ligand at the center
stage of tissue lipid homeostasis,
with promising therapeutic potential in
the context of diabetes, obesity, and
dyslipidemia.
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Pancreatic b cell failure is central in the pathogenesis of type 2 diabetes (T2D), but the mechanisms involved
remain unclear. Mahdi and colleagues (2012) couple global evaluation of gene expression with coexpression
network analysis of human islets from T2D patients to identify SFRP4 as an early mediator of b cell dysfunc-
tion in T2D.Genome-wide association studies for
T2D have so far identified 65 susceptibility
loci for the disease (Morris et al., 2012),
but together these loci account for less
than 10% of the variance in disease
susceptibility. This contrasts with the situ-
ation in type 1 diabetes (T1D), where such
studies have identified 50 loci across the
human genome associated with T1D that
explain nearly 80% of the heritability
(Pociot et al., 2010). Other approaches
to identify basic mechanisms of disease
are therefore needed (Taneera et al.,
2012). Furthermore, direct studies of the
diseased human tissue—in the case of
T2D, human islets are the gold standard
given the central role of b cell dysfunc-
tion in its pathogenesis—are essential to
further our understanding of human dia-
betes (Cnop et al., 2005; Kahn, 2003). In
this issue of Cell Metabolism, Mahdi and
colleagues tackle these challenges by
performing microarray analyses of human
islets isolated from T2D and normoglyce-
mic individuals (Mahdi et al., 2012) (Fig-
ure 1). They identify a group of T2D-
associated genes related to interleukin-1
(IL-1), a proinflammatory cytokine, andshow that secreted frizzled-related pro-
tein 4 (SFRP4) is highly associated
with T2D.
Previous work already suggested that
IL-1b plays a role in b cell dysfunction
and death in T1D and T2D. However,
whereas a role for inflammation in b cell
loss is well established in the context of
T1D (Eizirik et al., 2009), it has remained
controversial for T2D (Cnop et al., 2005;
Donath et al., 2008). To explain local
IL-1b production in the islets of T2D indi-
viduals, one model proposed that IL-1b
production was induced by glucose,
leading to upregulation of the apoptotic
Fas receptor and ligand and b cell
‘‘suicide’’ (Donath et al., 2008), but this
was not confirmed by other groups (re-
viewed in Cnop et al., 2005). In recent
years a more nuanced view of inflamma-
tion in T2D islets emerged, consisting
of mild upregulation of cytokines and
chemokines in islets from T2D patients,
possibly mediated by increased circu-
lating concentrations of the free fatty
acid palmitate that induces islet IL-1b
and TNF-a expression (Igoillo-Esteve
et al., 2010). Experimental findings showthat this metabolic ‘‘T2D-like’’ stress
induces a mild inflammatory response,
representing around 5%–10% of the pro-
inflammatory response of human islets
exposed to ‘‘T1D-like’’ conditions (Cnop
et al., 2005; Igoillo-Esteve et al., 2010).
The role for this ‘‘low-intensity’’ innate
immunity-mediated inflammation in b cell
dysfunction and death in T2D remains
unclear. For instance, an IL-1 receptor
antagonist blocked palmitate-induced
chemokine expression, but failed to pre-
vent apoptosis (Igoillo-Esteve et al., 2010).
Using gene expression topology with
weighted gene coexpression network
analysis (in which coexpressed genes
are clustered into gene modules based
on their connectivity), Mahdi et al. now
identify a T2D-related gene module en-
riched for IL-1-related genes. Among the
most connected hub genes, the authors
identify SFRP4 as highly associated with
T2D, HbA1c (a measure of average
glucose levels over the past 2 months),
and insulin secretion (Figure 1). Subse-
quent functional studies then show that
the SFRP4 protein is induced by the cyto-
kine IL-1b. Furthermore, the authors showNovember 7, 2012 ª2012 Elsevier Inc. 555
